先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02096 先声药业

交易中 12-19 11:10:45

6.670

-0.200

-2.91%

最高6.880	最低6.640	成交量123.40万
今开6.880	昨收6.870	日振幅3.49%
总市值168.54亿	流通市值168.54亿	总股本25.27亿
成交额824.75万	换手率0.05%	流通股本25.27亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02096","market":"HK","secType":"STK","nameCN":"先声药业","latestPrice":6.67,"timestamp":1734577751913,"preClose":6.87,"halted":0,"volume":1234000,"delay":0,"floatShares":2526816618,"shares":2526816618,"eps":0.293934,"marketStatus":"交易中","marketStatusCode":2,"change":-0.2,"latestTime":"12-19 11:10:45","open":6.88,"high":6.88,"low":6.64,"amount":8247528,"amplitude":0.034934,"askPrice":6.67,"askSize":25000,"bidPrice":6.66,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.4591908768759428,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1734580800000},"adr":0,"listingDate":1603728000000,"adjPreClose":6.87,"dividendRate":0.025732,"openAndCloseTimeList":[[1734571800000,1734580800000],[1734584400000,1734595200000]],"volumeRatio":0.839521,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02096/tweets","defaultTab":"tweets","newsList":[{"id":"2492198509","title":"交银国际：医保工作会议再提丙类目录和支持商保发展 关注政策宽松相关机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2492198509","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492198509?lang=zh_cn&edition=full","pubTime":"2024-12-19 09:31","pubTimestamp":1734571909,"startTime":"0","endTime":"0","summary":"全国医疗保障工作会议首提探索形成丙类目录。全国医疗保障工作会议共提出八大工作重点，其中多项措施明确支持商保发展。其中第五条“强化医保战略购买，赋能医药产业创新发展”指出，要“支持引导普惠型商业健康保险及时将创新药品纳入报销范围，研究探索形成丙类药品目录，并逐步扩大至其他符合条件的商业健康保险”。预计2025年，商保将有望迎来进一步发展，为解决创新药上市后的支付问题提供新的思路。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02096","BK1515","BK1521","LU1794554557.SGD","BK1583","LU0417516571.SGD","09926","IE00BPRC5H50.USD","01952","BK1191","LU2488822045.USD","LU0348783233.USD","BK1147","IE00B5MMRT66.SGD","IE00B543WZ88.USD","BK1589","BK1161","LU1720050803.USD","LU0348784397.USD","01177","BK1574","03329"],"gpt_icon":0},{"id":"2492891167","title":"【券商聚焦】交银国际预计2025年商保将有望进一步发展 协助解决创新药支付问题","url":"https://stock-news.laohu8.com/highlight/detail?id=2492891167","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492891167?lang=zh_cn&edition=full","pubTime":"2024-12-19 08:59","pubTimestamp":1734569982,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际预计2025年商保将有望进一步发展，协助解决创新药支付问题。同时，丙类目录+商保差异化发展的创新支付机制或缓解创新药械企业面临的进院难、报销支付难问题。近期医药板块在大幅震荡后有所回落，考虑到板块估值仍处于历史底部、叠加后续财政、医保/商保利好政策出台+流动性改善，该行认为仍有进一步修复空间。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949917","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","IE00BPRC5H50.USD","BK1589","LU0417516571.SGD","LU1720050803.USD","IE00B543WZ88.USD","09926","01177","BK1515","BK1521","159992","02096","06978","01952","BK1583","LU1794554557.SGD","BK1191","LU0348783233.USD","BK1147","LU0348784397.USD","BK1161","03329","BK1574","LU2488822045.USD"],"gpt_icon":0},{"id":"2490831842","title":"交银国际：予内地医药行业“领先”评级 上海设百亿人民币并购基金有利加速行业整合","url":"https://stock-news.laohu8.com/highlight/detail?id=2490831842","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490831842?lang=zh_cn&edition=full","pubTime":"2024-12-12 10:20","pubTimestamp":1733970040,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研究报告称，予内地医药行业“领先”评级。上海市发布文件，提出设立100亿元人民币生物医药产业并购基金，以推动行业的创新发展和并购重组，该行认为有利于加速行业的整合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177","09926","02096","01952"],"gpt_icon":0},{"id":"2490664010","title":"先声药业12月10日主力资金流出73万元 连续5日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2490664010","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490664010?lang=zh_cn&edition=full","pubTime":"2024-12-10 16:16","pubTimestamp":1733818565,"startTime":"0","endTime":"0","summary":"12月10日, 先声药业股价跌3.69%，报收7.05元，成交金额3198万元，换手率0.18%，振幅6.01%，量比0.62。先声药业今日主力资金净流出73万元，连续5日净流出，上一交易日主力净流出250万元，今日环比减少70.80%。近一年数据显示，该股主力连续5日净流出后，次日下跌概率为60.00%，平均跌幅为1.53%。该股近5个交易日下跌4.47%，主力资金累计净流出907万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出1375万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210161630ab6c311b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210161630ab6c311b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","02096","BK1191"],"gpt_icon":0},{"id":"2490608793","title":"先声再明新型Polθ抑制剂SIM0508完成全球首例患者用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2490608793","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490608793?lang=zh_cn&edition=full","pubTime":"2024-12-09 10:16","pubTimestamp":1733710577,"startTime":"0","endTime":"0","summary":"每经AI快讯，据“先声药业”公众号消息，先声药业集团旗下的抗肿瘤创新药公司先声再明宣布，其自主研发的Polθ抑制剂SIM0508用于晚期实体瘤的临床研究已于近日在复旦大学附属肿瘤医院实现全球首例患者用药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202412093262676929.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412093262676929.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","02096","BK1191"],"gpt_icon":0},{"id":"2490600317","title":"先声再明新型Polθ抑制剂SIM0508完成全球首例患者用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2490600317","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490600317?lang=zh_cn&edition=full","pubTime":"2024-12-09 10:06","pubTimestamp":1733710002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1574","159992","BK1583","BK1191","06978","BK1161","02096"],"gpt_icon":0},{"id":"2489252972","title":"先声药业脑卒中创新药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2489252972","media":"广州日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489252972?lang=zh_cn&edition=full","pubTime":"2024-12-07 22:03","pubTimestamp":1733580230,"startTime":"0","endTime":"0","summary":"日前，先声药业脑细胞保护创新药先必新舌下片获批上市，可为卒中患者提供脑细胞保护，有效降低患者残疾率，未来有望成为卒中发生后的急救用药，市场空间或达百亿元。据悉，卒中分为缺血性卒中和出血性卒中，缺血性卒中占比超60%。“对急性缺血性卒中的脑细胞保护治疗，一直是世界难题。脑细胞死亡越多，未来残疾风险越高。”首都医科大学附属北京天坛医院院长王拥军表示。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412073262069936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02096","BK1161","BK1191","BK1583","BK1574","06978"],"gpt_icon":0},{"id":"2489401451","title":"先声药业12月06日主力资金流出321万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2489401451","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489401451?lang=zh_cn&edition=full","pubTime":"2024-12-06 16:15","pubTimestamp":1733472928,"startTime":"0","endTime":"0","summary":"12月06日, 先声药业股价跌3.01%，报收7.08元，成交金额3223万元，换手率0.18%，振幅3.42%，量比0.69。先声药业今日主力资金净流出321万元，连续3日净流出，上一交易日主力净流出198万元，今日环比增加62.12%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为40.00%，平均跌幅为3.02%。该股近5个交易日上涨1.00%，主力资金累计净流入482万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出1040万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206161549ab6206dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206161549ab6206dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","02096","BK1191"],"gpt_icon":0},{"id":"2489423513","title":"交银国际：全国中药饮片、中成药集采开启 关注后续医保政策宽松相关机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2489423513","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489423513?lang=zh_cn&edition=full","pubTime":"2024-12-06 10:00","pubTimestamp":1733450445,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研究报告称，2024年全国中药饮片、中成药集采正式启动。全国中药饮片联采扩展至全国范围，共涉及45个品种，降幅20%以上、价差1.2倍是拟中选的关键因素。此次纳入了17种中药注射剂，包含双黄连注射液、舒肝宁注射液。此外，27省联盟耗材集采结果也公布。此轮集采共181家企业参加线上会议并报价。从结果来看，有154家企业拟中选，企业拟中选率85%，拟中选产品平均降幅70%，与前两轮生化试剂集采的降幅区间相似。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348783233.USD","03329","LU0348784397.USD","02096","BK1191","BK1521","01177","01952","09926","BK1583","IE00B5MMRT66.SGD","LU1794554557.SGD","BK1515","BK1147","IE00BPRC5H50.USD","LU2488822045.USD","LU0417516571.SGD","BK1161","IE00B543WZ88.USD","BK1574","BK1589","LU1720050803.USD"],"gpt_icon":0},{"id":"2489444743","title":"【券商聚焦】交银国际指医药板块仍有进一步修复空间 重点推荐医保谈判的受益标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2489444743","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489444743?lang=zh_cn&edition=full","pubTime":"2024-12-06 09:11","pubTimestamp":1733447499,"startTime":"0","endTime":"0","summary":"近期医药板块在大幅震荡后小幅回升，考虑到板块估值仍处于历史底部、叠加后续财政、医保/商保利好政策出台+流动性改善，该行认为仍有进一步修复空间。同时建议关注：1）消费属性较强的民营医疗服务和医美标的；2）股息率高、有望受益于行业整体基本面改善的医药商业流通标的。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/YzgwMTczMTA1NDUyODEwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzgwMTczMTA1NDUyODEwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949095","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","IE00B5MMRT66.SGD","01177","BK1574","BK1589","BK1161","LU1720050803.USD","01952","159938","BK1521","LU0348783233.USD","LU1794554557.SGD","LU2488822045.USD","IE00B543WZ88.USD","BK1583","02096","09926","BK1191","LU0417516571.SGD","03329","09939","LU0348784397.USD","BK1147","IE00BPRC5H50.USD"],"gpt_icon":0},{"id":"2489439773","title":"先声药业12月05日遭主力抛售198万元 环比增加191.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2489439773","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489439773?lang=zh_cn&edition=full","pubTime":"2024-12-05 16:15","pubTimestamp":1733386538,"startTime":"0","endTime":"0","summary":"12月05日, 先声药业股价跌1.08%，报收7.30元，成交金额2295万元，换手率0.12%，振幅1.76%，量比0.43。先声药业今日主力资金净流出198万元，上一交易日主力净流出68万元，今日环比增加191.18%。该股近5个交易日上涨5.48%，主力资金累计净流入267万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出784万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205161604ab5f348b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205161604ab5f348b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02096","BK1583"],"gpt_icon":0},{"id":"1102887225","title":"异动解读 | 先声药业脑卒中创新药新剂型获批上市推动股价大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102887225","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102887225?lang=zh_cn&edition=full","pubTime":"2024-12-03 17:26","pubTimestamp":1733217997,"startTime":"0","endTime":"0","summary":"先声药业(02096)今日盘中大涨5.01%,引发市场广泛关注。\n\n消息面上,先声药业的脑细胞保护创新药先必新舌下片获得国家药品监督管理局批准上市,用于改善急性缺血性脑卒中所致的神经症状、日常生活活动能力和功能障碍。该药使用了双靶点作用机制,可显著减少卒中导致的脑细胞损伤。\n\n先声药业之前在2020年就已获批上市了先必新注射剂剂型。此次先必新舌下片的获批,将与注射剂形成序贯治疗,有望覆盖卒中全病程,发挥协同效应。根据数据,我国卒中治疗药物市场规模超过1300亿元,且仍保持较快增长,先必新获批上市后有望快速放量。同时,先必新舌下片也计划开展全球多中心临床研究。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02096"],"gpt_icon":0},{"id":"2488964453","title":"【券商聚焦】华泰证券升先声药业(02096)目标价22% 料业绩有望重回快速增长轨道","url":"https://stock-news.laohu8.com/highlight/detail?id=2488964453","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488964453?lang=zh_cn&edition=full","pubTime":"2024-12-03 15:47","pubTimestamp":1733212045,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰证券发研报指，12月2日，先声药业 公告先必新舌下片获NMPA批准在中国上市，用于治疗AIS。此外，公司在国谈中先必新降价温和，新品成功纳入；叠加新品陆续获批带来增量，该行看好公司业绩复苏。该行亦看好公司的差异化创新早研管线，其中的领先者颇具全球潜力。该行维持2024/2025/2026年经调整净利润为9.5/13.7/17.7亿元，对应经调整EPS 0.38/0.54/0.70元，给予18.53x PE，目标价10.75港币。维持“买入”评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/YzgwMTczMTA1NDUyODEwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzgwMTczMTA1NDUyODEwNQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1948874","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"gpt_icon":0},{"id":"2488951655","title":"先声药业早盘涨超6% 先必新舌下片获国家药监局批准在中国上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2488951655","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488951655?lang=zh_cn&edition=full","pubTime":"2024-12-03 10:02","pubTimestamp":1733191320,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　先声药业（02096）早盘上涨6.45%，现报7.43港元，成交额5049.47万港元。\n　　先声药业发布公告，2024年12月1日，先必新舌下片（依达拉奉右莰醇舌下片）获中国国家药品监督管理局（NMPA）批准在中国上市，用于改善急性缺血性脑卒中（“AIS”）所致的神经症状、日常生活活动能力和功能障碍。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-12-03/doc-incycyit1787881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","02096","BK1583"],"gpt_icon":0},{"id":"2488939835","title":"港股异动 | 先声药业(02096)早盘涨近6% 先必新舌下片获国家药监局批准在中国上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2488939835","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488939835?lang=zh_cn&edition=full","pubTime":"2024-12-03 09:33","pubTimestamp":1733189634,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，先声药业(02096)早盘涨近6%，截至发稿，涨4.58%，报7.3港元，成交额1072.59万港元。消息面上，先声药业发布公告，2024年12月1日，先必新舌下片(依达拉奉右莰醇舌下片)获中国国家药品监督管理局(NMPA)批准在中国上市，用于改善急性缺血性脑卒中(“AIS”)所致的神经症状、日常生活活动能力和功能障碍。据先声药业9月2日公告，先必新舌下片获美国食品药品监督管理局（FDA）“突破性疗法”认定，是全球脑卒中治疗领域首个获得该认定的创新药。临床研究表明，先必新舌下片能够显著减少急性缺血性卒中导致的脑细胞损伤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219443.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1191","02096"],"gpt_icon":0},{"id":"2488464931","title":"先声药业盘中异动 急速上涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488464931","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488464931?lang=zh_cn&edition=full","pubTime":"2024-12-03 09:33","pubTimestamp":1733189600,"startTime":"0","endTime":"0","summary":"2024年12月03日早盘09时33分，先声药业股票出现异动，股价急速拉升5.01%。截至发稿，该股报7.330港元/股，成交量141.6万股，换手率0.06%，振幅5.16%。资金方面，该股资金流入755.005万港元，流出146.44万港元。先声药业股票所在的药品行业中，整体跌幅为0.14%。其相关个股中，先声药业、联康生物科技集团、翰森制药涨幅较大，振幅较大的相关个股有先声药业、联康生物科技集团、翰森制药，振幅分别为5.16%、3.17%、2.96%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203093320971b4298&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203093320971b4298&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02096","BK1583"],"gpt_icon":0},{"id":"2488293146","title":"南向资金12月2日净买入先声药业116.30万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2488293146","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488293146?lang=zh_cn&edition=full","pubTime":"2024-12-03 09:30","pubTimestamp":1733189413,"startTime":"0","endTime":"0","summary":"12月2日, 南向资金增持先声药业116.30万股，连续3日增持。截止当日收盘，港股通共持有先声药业29746.42万股，占流通股11.76%。先声药业近5个交易日上涨5.92%，港股通累计增持212.10万股；近20个交易日上涨1.60%，港股通累计增持1747.40万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203093155abf144fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203093155abf144fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1191","02096"],"gpt_icon":0},{"id":"2488198719","title":"智通港股早知道 | 央行修订M1统计口径 香港11月整体楼宇买卖合约登记总值创4月来新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2488198719","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488198719?lang=zh_cn&edition=full","pubTime":"2024-12-03 07:18","pubTimestamp":1733181533,"startTime":"0","endTime":"0","summary":"香港11月份整体楼宇买卖合约登记总值环比上升53.8% 创今年4月来新高智通财经APP获悉，中原地产研究部高级联席董事杨明仪指出，11月份香港整体楼宇买卖合约登记7678宗，总值640.73亿港元，环比分别上升31.1%及53.8%，宗数及金额齐创今年4月后新高。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1133","BK1593","BK1191","IE00BMCWC346.EUR","SG9999015952.SGD","IE00BYV24P56.USD","YANG","BK1536","HSTECH","LU2488822045.USD","00867","SG9999015945.SGD","SG9999015978.USD","01310","BK1583","02096","SG9999004220.SGD","SG9999015986.USD","HSCEI"],"gpt_icon":1},{"id":"2488341349","title":"先声药业(2096.HK)：先必新舌下片获批 新一轮增长启航","url":"https://stock-news.laohu8.com/highlight/detail?id=2488341349","media":"华泰证券","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488341349?lang=zh_cn&edition=full","pubTime":"2024-12-03 00:00","pubTimestamp":1733155200,"startTime":"0","endTime":"0","summary":"12 月2 日，公司公告先必新舌下片获NMPA 批准在中国上市，用于治疗AIS。舌下片给药、储存便捷，方便患者在卒中发生后及时给药，并利于出院后使用，且可满足患者备药需求。舌下片有望与现有的注射液以序贯疗法等方式形成协同效应，启动先声药业中枢神经领域新一轮增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203102131a268042c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203102131a268042c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02096","BK1583"],"gpt_icon":0},{"id":"2488608274","title":"心脉医疗需补缴超6000万元税款及滞纳金，先声药业脑卒中创新药获批上市，华纳药厂宣布减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2488608274","media":"谈医说药","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488608274?lang=zh_cn&edition=full","pubTime":"2024-12-02 23:41","pubTimestamp":1733154098,"startTime":"0","endTime":"0","summary":"本次获得该药物补充申请批准通知书，对公司当期业绩无重大影响。诚如公司日期为2024年6月23日之公告所载，集团的依托咪酯原料药已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。截至目前，氟唑帕利相关项目累计已投入研发费用约10.05亿元。公司将予以补缴，并已就取消高企资格提出书面异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202234904a266c0b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202234904a266c0b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","688799","BK1191","BK1583","02096","BK1161","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.simcere.com","stockEarnings":[{"period":"1week","weight":-0.0255},{"period":"1month","weight":0.0029},{"period":"3month","weight":0.1063},{"period":"6month","weight":0.2116},{"period":"1year","weight":0.1043},{"period":"ytd","weight":0.0519}],"compareEarnings":[{"period":"1week","weight":-0.0144},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.1018},{"period":"1year","weight":0.2035},{"period":"ytd","weight":0.1653}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"先声药业集团有限公司是一家从事药品的研发、生产和销售的公司。该公司的主要产品为仿制药，包括用于中枢神经系统疾病的产品必存、用于肿瘤疾病的产品捷百舒和捷佰立、以及用于自身免疫疾病的产品英太青。该公司还从事生产创新药，比如用于肿瘤疾病的恩度。该公司还从事为医疗机构销售的第三方药品提供推广服务。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.125153},{"month":2,"riseRate":0.5,"avgChangeRate":0.05159},{"month":3,"riseRate":0.5,"avgChangeRate":-0.025896},{"month":4,"riseRate":0.5,"avgChangeRate":-0.016117},{"month":5,"riseRate":0.75,"avgChangeRate":0.081955},{"month":6,"riseRate":0.75,"avgChangeRate":0.075768},{"month":7,"riseRate":0,"avgChangeRate":-0.112762},{"month":8,"riseRate":0.25,"avgChangeRate":-0.080804},{"month":9,"riseRate":0.5,"avgChangeRate":-0.013619},{"month":10,"riseRate":1,"avgChangeRate":0.140792},{"month":11,"riseRate":0.6,"avgChangeRate":0.032389},{"month":12,"riseRate":0.4,"avgChangeRate":0.018582}],"exchange":"SEHK","name":"先声药业","nameEN":"SIMCERE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供先声药业(02096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"先声药业,02096,先声药业股票,先声药业股票老虎,先声药业股票老虎国际,先声药业行情,先声药业股票行情,先声药业股价,先声药业股市,先声药业股票价格,先声药业股票交易,先声药业股票购买,先声药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供先声药业(02096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}